Journals / İnfeksiyon Dergisi / 2003 / Cilt: 17 - Sayı: 4

Enzyme immunoassay in the serologic diagnosis of Chlamydia pneumoniae in atherosclerotic cardiac disease

Aterosklerotik kalp hastalarında Chlamydia pneumoniae'nin serolojik tanısında enzim immunoassay (EIA)'in kullanımı

Pages
409–414
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was concluded that, because of EIA is genus-specific, new species-specific commercial kits are needed for the serological diagnosis of chronic C. pneumoniae infection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to evaluate enzyme-immunoassay EIA in the detection of IgA, IgM and IgG antibodies in the serological diagnosis of C. pneumoniae infection.
📊
Key Findings & Data:Seventy-one patients, diagnosed as atherosclerotic heart disease and 20 patients as control group, totally 91 patients, were studied.
💡
Conclusion & Impact:It was concluded that, because of EIA is genus-specific, new species-specific commercial kits are needed for the serological diagnosis of chronic C. pneumoniae infection.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to evaluate enzyme-immunoassay EIA in the detection of IgA, IgM and IgG antibodies in the serological diagnosis of C. pneumoniae infection. Seventy-one patients, diagnosed as atherosclerotic heart disease and 20 patients as control group, totally 91 patients, were studied. ImmunglobulinA, IgM and IgG antibodies against C. pneumoniae were detected by EIA and micro-immunflorescence (MIF) methods. Chlamydia pneumoniae IgM positivites were 12% with both of EIA and MIF; IgA positivities 52% with EIA and 44% with MIF; IgG positivities 85.3% in with EIA and 45.3% with MIF. It was concluded that, because of EIA is genus-specific, new species-specific commercial kits are needed for the serological diagnosis of chronic C. pneumoniae infection.

Özet

Bu çalışmada; Chlamydia pneumoniae. infeksiyonunun serolojik tanısında kullanılan IgA, IgM ve IgG antikorlarının saptanmasında enzim-immonassay (EIA)'in değerlendirilmesi amaçlanmıştır. Aterosklerotik kalp hastalığı tanısı konulan 71, kontrol grubu olarak 20 olmak üzere toplam 91 hasta çalışmaya alındı. Chlamydia pneumoniae'ye karşı oluşan IgA, IgM ve IgG antikorları EIA ve mikro-immunofloresans (MIF) yöntemleri ile saptandı. Chlamydia pneumoniae IgM pozitifliği EIA ve MIF yöntemlerinin her ikisi ile %12; IgA pozitifliği EIA yöntemi ile %52, MIF yöntemi ile % 44; IgG pozitifliği ise EIA yöntemi He %85.3, MIF yöntemi ile %45.3 olarak saptandı. Kronik C. pneumoniae infeksiyonunun serolojik tanısında ElA'in cinse özgül olması nedeni ile uygun olmadığı, türe özgül yeni ticari kitlere gereksinim olduğu sonucuna ulaşıldı.

🔖

Cite This Article

AYDINLI, A., DURMAZ, G., AKGÜN, Y., ÜNALIR, A., US, T. (2022). Enzyme immunoassay in the serologic diagnosis of Chlamydia pneumoniae in atherosclerotic cardiac disease. İnfeksiyon Dergisi, Cilt: 17 - Sayı: 4, 409–414. https://ajindex.com/articles/546652

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Odeh M, Oliven A. Chlamydial infections of heart. Eur J Microbiol Infect Dis 1992; 11: 885-93
  2. Schachter J, Stamm WE. Chlamydia. In: Manual of Clinical Microbiology. Washington DC: ASM Press, 1995: 669-77
  3. Bavoil P, Ohlin A, Schachter J. Role of disulfid bonding in outer membran structure and permeability in C. trachomatis. Infect Immun 1984; 44: 479-85
  4. Tuuminen T, Palomaki P, Paavonen J. The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Methods 2000; 42: 265-79
  5. Gwendolyn LG. Chlamydia. In: Gwendolyn LG, ed. Practical Medical Microbiology. New York: Churchill-Livingstone Co, 1996: 621-33
  6. An¤ Ö, Badur S, A¤açfidan A, ed. Chlamydia ‹nfeksiyonlar› ve Tan›da Yenilikler. Türk Mikrobiyoloji Cemiyeti Yay›n› No: 20. ‹stanbul: ‹stanbul Üniversitesi Bas›mevi ve Film Merkezi, 1994
  7. Gnarpe J, Naas J, Lundback A. Comparison of a new commercial EIA kit and the microimmunofluorescence technique for the determination of IgG and IgA antibodies to Chlamydia pneumoniae. APMIS 2000; 108: 819-24
  8. Messmer TO, Martinez J, Hassouna F, et al. Comparison of two commercial microimmunofluorescence kits and an enzyme immunoassay kit for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae. Clin Diagn Lab Immunol 2001; 8: 588-92
  9. Halvorsen DS, Borvik T, Njolstad I, Gutteberg TJ, Vorland LH, Hansen JB. Chlamydia pneumoniae IgA-and IgG antibodies in young survivors of mycardial infarction. A comparison of antibody detection by a microimmunofluorescence test and an enzyme immunoassay. J Intern Med 2002; 251: 142-7
  10. Fryden A, Kihlström E, Maller R, Person K, Romanus V, Ansehn S. A clinical and epidemiological study of "ornithosis" caused by Chlamydia psittaci and Chlamydia pneumoniae (Strain TWAR). Scand J Infect Dis 1989; 21: 681-91
  11. Mattila KJ. Viral and bacterial infections in patients with acute mycardial infarction. J Intern Med 1989; 225: 293-6
  12. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996; 125: 979-82
  13. Carlisle SS, Nahata MC. Chlamydia pneumoniae and coronary heart disease. Ann Pharmacother 1999; 33: 615-22
  14. Vercellotti G. Infectious agents that play a role in atherosclerosis and vasculopathies. What are they? What do we do about them? Can J Cardiol 1999; 15 (Suppl B): 13-5
  15. Jackson LE, Campbell LA, Schmidt RA, et al. Specifity of detection of Chlamydia pneumoniae in cardiovascular atherom